Dosing Commenced in Study of Anti-Tau Agent, FDA Updates Labeling to Glatiramer Acetate Products, Eisai Initiates ...
WATCH TIME: 4 minutes Welcome to this special edition of Neurology News Network. I’m Marco Meglio. According to a new announcement, the first participants in a phase 1 study assessing Voyager Therapeutics’ anti-tau antibody VY-TAU01, an investigational …